IMO, Addex has a decent possibility of a partnership for Dipraglurant Phase III, expected to start early next year. It would be nice to put that in place before they need to raise more capital. It has FDA OD status, and Phase II results were very positive (no AE's and clear efficacy) and now published in peer-review journals.
If they can get one molecule off the ground, it would help validate their entire allosteric discovery platform, and long-term Addex could be a multi $bn company.